Related Experiment Video

Updated: Jun 3, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus

Pamela Kushner1

  • 1University of California, Irvine College of Medicine, California, USA.

Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
|March 26, 2011
PubMed

Insights

Hypoglycemia poses significant risks for type 2 diabetes mellitus patients, impacting long-term health and increasing mortality. Physicians should prioritize individualized treatment plans to avoid hypoglycemia, utilizing safer medication combinations.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Hypoglycemia is a significant challenge in diabetes management, hindering glycemic control.
  • Both acute and recurrent hypoglycemia can lead to serious long-term complications in type 2 diabetes mellitus (T2DM).
  • Consequences include impaired counterregulation, hypoglycemia unawareness, increased hospitalizations, and mortality.

Purpose of the Study:

  • To highlight the detrimental effects of hypoglycemia in T2DM.
  • To emphasize the importance of avoiding hypoglycemia in treatment strategies.
  • To suggest therapeutic approaches for achieving glycemic goals safely.

Main Methods:

  • Review of existing literature on hypoglycemia in T2DM.
  • Analysis of the long-term consequences of hypoglycemic events.
  • Evaluation of current and emerging pharmacologic treatments for T2DM.

Main Results:

  • Recurrent hypoglycemia can lead to hypoglycemia unawareness and increased severe events.
  • Hypoglycemia is associated with negative cardiovascular and cognitive outcomes.
  • Individualized treatment regimens are crucial for mitigating hypoglycemia risks.

Conclusions:

  • Avoiding hypoglycemia should be a primary physician focus in T2DM management.
  • Combining traditional agents (metformin, thiazolidinediones) with newer agents (DPP-4 inhibitors, incretin mimetics) may offer a safer therapeutic strategy.
  • Achieving hemoglobin A1c goals without increasing hypoglycemia risk is attainable with appropriate medication selection.
Keywords:
diabetes managementdipeptidyl peptidase-4 inhibitorshypoglycemiaincretintype 2 diabetes mellitus

More Related Videos

Hyperglycemic Clamp and Hypoglycemic Clamp in Conscious Mice07:35

Hyperglycemic Clamp and Hypoglycemic Clamp in Conscious Mice

Published on: January 26, 2024

Related Concept Videos

Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...